Discover

Back to filter

Related topics

Cytek webinar : Evaluating Spectral Cytometry for Immune Profiling in Viral Disease

Cytek Biosciences

May 13, 2021

In conventional fluorescence cytometry, each fluorophore in a panel is measured in a...

Introducing ExoFlex - The latest assay for customized EV detection

NanoView Biosciences

May 11, 2021

ExoFlex allows users to customize the detection of EVs via any custom antibody. Nanoview...

Developing tools for multiplex to single EV analysis pipelines

Cytek Biosciences

May 10, 2021

Extracellular vesicles (EVs) are lipid spheres released from cells. EVs express proteins...

Single-cell DNA Analysis of a Novel Acute Erythroid Leukemia CRISPR Induced Mouse Model

Mission Bio

May 9, 2021

Assessment of precise genetic edits. Analysis of the clonal structure & co-mutations of AEL. Use of CRISPR and...

SARS-CoV-2 detection workflow in wastewater - Analytik Jena and project in Japan

Analytik Jena

May 8, 2021

In 2020 Analytik Jena real-time PCR thermal cyclers of the qTOWER³ series even supported one of the first SARS-CoV-2...

The impact of environmental Oxygen content on Natural Killer Cell Immunotherapy

Xcell Biosciences

May 7, 2021

Natural Killer (NK) cells are being studied in the clinic in a number of settings,...

Rethinking 3D cell culture with IncuCyte: advanced cell cultures from iPSCs and organoids

Sartorius

May 6, 2021

The world is neither flat nor two-dimensional, so why should cell culture be? Traditional...

Build your experiments online with new Spectrum Viewer and SpectroFlo Experiment Builder

Cytek Biosciences

May 5, 2021

Explore new capabilities of Cytek's Full Spectrum Viewer and complementary SpectroFlo...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey